diphtheria and tetanus toxoids


Also found in: Dictionary, Encyclopedia.
Related to diphtheria and tetanus toxoids: DPT vaccine, DT vaccine

diphtheria and tetanus toxoids (DT)

an active immunizing agent.
indications It is prescribed for immunization against diphtheria and tetanus when pertussis vaccination is contraindicated.
contraindications Immunosuppression, acute infection, or concomitant use of corticosteroids prohibits its use.
adverse effect The most serious adverse reaction is anaphylaxis.
References in periodicals archive ?
All children received the same amount of diphtheria and tetanus toxoid and associated alum adjuvant.
Adolescents aged 11 through 18 years who have completed the recommended childhood diphtheria and tetanus toxoids and pertussis vaccine (DTP/DTaP) vaccination series should receive a single dose of Tdap instead of tetanus and diphtheria toxoids (Td) vaccine, preferably at a preventive-care visit at age 11 or 12 years (4).
The decision to create the stockpile was triggered by previous shortages of vaccines, including trivalent influenza vaccine (TIV), tetanus and diphtheria toxoids (Td), diphtheria and tetanus toxoids and acellular pertussis (DTaP), and pneumococcal conjugate vaccine (PCV), a spokesman for the Department of Health and Human Services told this newspaper.
Aventis Pasteur is now producing Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DAPTACEL), which was recently licensed for the first four DTaP doses, and will continue to produce Tripedia as well.
ACIP recommends a single Tdap dose for persons aged 11 through18 years who have completed the recommended childhood diphtheria and tetanus toxoids and pertussis/diphtheria and tetanus toxoids and acellular pertussis (DTP/DTaP) vaccination series and for adults aged 19 through 64 years (4,5).
Pertussis antibody concentrations for pertussis toxoid (PT), filamentous hemagglutinin (FHA), and pertactin in the first clinical trial were noninferior to those of infants after a primary diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccination series with Infanrix (GlaxoSmithKline Biologicals, Rixensart, Belgium) in a clinical trial in which efficacy of DTaP also was demonstrated (4-6).
On June 24, 2008, the Food and Drug Administration licensed a combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP) and inactivated poliovirus (IPV) vaccine, DTaP-IPV (Kinrix, GlaxoSmithKline Biologicals, Rixensart, Belgium).
On June 20, 2008 the Food and Drug Administration (FDA) licensed a combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP), inactivated poliovirus vaccine (IPV), and Haemophilus influenzae type b conjugate (tetanus toxoid [TT] conjugate) vaccine, DTaP-IPV/Hib (Pentacel, Sanofi Pasteur, Swiftwater, Pennsylvania), for use as a four-dose series in infants and children at ages 2, 4, 6, and 15-18 months (1,2).
For these children, the target is [greater than or equal to] 95% vaccination coverage for the following: hepatitis B vaccine; diphtheria and tetanus toxoids and pertussis vaccine, diphtheria and tetanus toxoids and acellular pertussis vaccine, or diphtheria and tetanus toxoids vaccine (DTP/ DTaP/DT); poliovirus vaccine; measles, mumps, and rubella (MMR) vaccine; and varicella vaccine (1).
Full browser ?